Cardiol Therapeutics INC F-1 registration statements

Cardiol Therapeutics Inc. amended its shelf prospectus for a potential US$150 million securities offering, highlighting positive clinical data for CardiolRx in recurrent pericarditis and FDA Orphan Drug Designation.

Cardiol Therapeutics has filed an amendment to its registration statement, allowing for the potential offering of up to US$150 million in various securities over a 25-month period.

Cardiol Therapeutics has filed a preliminary short form base shelf prospectus to offer up to US$150 million in common shares, debt securities, warrants, subscription receipts, or units over a 25-month period.